NCT06998771尚未招募2 期
A Phase II Trial to Evaluate the Safety and Efficacy of JSKN003 Combination Therapy as First-line Treatment in HER2-positive Unresectable Locally Advanced or Metastatic Gastric Cancer or Resectable Gastric Cancer
Shanghai JMT-Bio Inc.0 个研究点目标入组 153 人开始时间: 2025年6月15日最近更新:
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 153
- 主要终点
- Objective Response Rate (ORR) of the first-line population
研究概览
简要总结
This study is designed to evaluate the safety and efficacy of JSKN003 combination therapy as first-line treatment in HER2-positive unresectable locally advanced or metastatic gastric cancer or resectable gastric cancer.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age≥18 years old.
- •Histologically or cytologically confirmed diagnosis of gastric cancer.
- •The first-line population enrolls participants with HER2-positive unresectable locally advanced or metastatic gastric cancer who had not received systemic treatment, and Perioperative population enrolls participants with HER2-positive resectable gastric cancer who had not received treatment.
- •HER2-positive (defined as IHC3+ or IHC 2+/FISH +).
- •The first-line population: presence of at least 1 measurable lesion per RECIST 1.
- •Tumor lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions.
- •ECOG PS of 0 -
- •Expected survival ≥ 3 months.
- •Participants with adequate organ functions.
- •Female and male patients of childbearing age agree to take adequate contraceptive measures during and upon completion of the study for 7 months after the last dose. Female participants of childbearing age must have a negative blood pregnancy test within 7 days before the first dose or randomization.
- •Voluntarily agree to participate in the study and sign the informed consent.
排除标准
- •Has received anti-tumor treatment such as systemic chemotherapy or other trial interventions within 28 days, or immunotherapy (e.g. interleukin, interferon, thymospipeptide, etc.), hormone therapy or targeted therapy within 14 days or 5 half-life (whichever is shorter) before the first dose or randomization.
- •Has previously been treated with an anti-HER2 ADC loaded with topoisomerase I inhibitors.
- •Participants with brain metastasis or spinal cord compression at screening (except for completed local treatment and discontinued glucocorticoids for at least 4 weeks before the first dose or randomization , and stable central nervous system imaging and brain metastasis symptoms for at least 4 weeks).
- •Participants with PD-L1 CPS ≥1, who are receiving long-term immunotherapy (e.g., cyclosporine) or require daily systemic steroid therapy (e.g., >20 mg prednisone or equivalent), except those who treated with local glucocorticoids using nasal spray, inhalation, or other pathways.
- •Participants with PD-L1CPS ≥1, who have an active autoimmune disease or have a history of autoimmune disease 2 years before the first dose or randomization and still require systemic treatment. However, participant with the following diseases is allowed to enroll: well-controlled type I diabetes, well-controlled hypothyroidism that requires hormone replacement therapy, skin diseases that do not require systemic treatment (such as vitiligo, psoriasis, or hair loss), or participant who is expected to not recur without external triggers.
- •Participate in another clinical trial, unless it is an observational (non-intervention) clinical trial or is in the follow-up period of an intervention trial.
- •Participants who have undergone major surgery or had invasive intervention within 28 days before the first dose or randomization. Or those who plan to undergo systematic or local tumor resection during the trial (Perioperative cohort does not apply).
- •Any Chinese patent medicine with anti-cancer activity approved by the National Drug Administration (regardless of cancer type) has been used within 14 days before the first dose or randomization.
- •Has a history of severe hypersensitivity reactions to either the drug substances or inactive ingredients in the drug product.
- •Active bacterial, fungal or viral infection before the first dose or randomization. Participant who has recieved preventive infection treatment but has no clinical manifestations before the first dose or randomization could be considered to enroll.
- •Has a history of immunodeficiency, including HIV-positive.
- •Active hepatitis B or C infection. Participant with positive hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) need to test Hepatitis B virus DeoxyriboNucleic Acid (HBV-DNA), and HBV-DNA is higher than 500 IU/mL (or 2500 copies/ml) or upper limit of normal (UNL) (whichever is lower) ; Participants with positive for hepatitis C (HCV) antibody and whose Hepatitis C virus Ribonucleic Acid (HCV-RNA) is higher than 1000 copies/ml or UNL (whichever is lower).
- •Has a history of tuberculosis treatment within 2 years before the first dose or randomization.
- •Has activity or a history of interstitial lung disease at any stage and/or pulmonary function injury, a history of interstitial pneumonia requiring hormone therapy, or the imaging cannot rule out suspected interstitial lung disease/pneumonia at screening.
- •Known to have low activity or lack of dihydropyrimidine dehydrogenase (DPD).
- •Participants with peripheral neuropathy of grade >
- •Participants with clinically significant gastrointestinal diseases including but not limited to severe liver diseases, ulcerative colitis, inflammatory bowel disease and other gastrointestinal diseases 28 days before the first dose or randomization.
- •Has a history of severe cardiovascular disease.
- •History of any other malignant tumors within 5 years before the first dose or randomization.
- •Live vaccination within 28 days before the first dose or randomization. Note: Seasonal influenza vaccine is a broadly inactivated vaccine and is allowed to be used;
- •Unable to swallow orally, or there are conditions that have been judged by researchers to seriously affect gastrointestinal absorption (such as severe Crohn's disease, malabsorption syndrome, etc.).
- •Pregnant or breastfeeding women.
- •Otherwise considered inappropriate for the study by the investigator.
研究组 & 干预措施
Combination of JSKN003, capecitabine and oxaliplatin with or without enlonstobart
Experimental
干预措施: JSKN003 (Drug)
Combination of JSKN003 and capecitabine with or without enlonstobart
Experimental
干预措施: JSKN003 (Drug)
Combination of JSKN003 and capecitabine with or without enlonstobart
Experimental
干预措施: Capecitabine (Drug)
Combination of JSKN003 and capecitabine with or without enlonstobart
Experimental
干预措施: Enlonstobart (Drug)
Combination of JSKN003, capecitabine and KN026 with or without enlonstobart
Experimental
干预措施: JSKN003 (Drug)
Combination of JSKN003, capecitabine and KN026 with or without enlonstobart
Experimental
干预措施: KN026 (Drug)
Combination of JSKN003, capecitabine and KN026 with or without enlonstobart
Experimental
干预措施: Capecitabine (Drug)
Combination of JSKN003, capecitabine and KN026 with or without enlonstobart
Experimental
干预措施: Enlonstobart (Drug)
Combination of JSKN003, capecitabine and oxaliplatin with or without enlonstobart
Experimental
干预措施: Capecitabine (Drug)
Combination of JSKN003, capecitabine and oxaliplatin with or without enlonstobart
Experimental
干预措施: Enlonstobart (Drug)
Combination of JSKN003, capecitabine and oxaliplatin with or without enlonstobart
Experimental
干预措施: Oxaliplatin (Drug)
Combination of trastuzumab, capecitabine and oxaliplatin with or without pembolizumab
Experimental
干预措施: Capecitabine (Drug)
Combination of trastuzumab, capecitabine and oxaliplatin with or without pembolizumab
Experimental
干预措施: Oxaliplatin (Drug)
Combination of trastuzumab, capecitabine and oxaliplatin with or without pembolizumab
Experimental
干预措施: Trastuzumab (Drug)
Combination of trastuzumab, capecitabine and oxaliplatin with or without pembolizumab
Experimental
干预措施: Pembolizumab (Drug)
结局指标
主要结局
Objective Response Rate (ORR) of the first-line population
时间窗: Frame: Up to approximately 5 years
Incidence and severity of TEAE and SAE of the first-line population
时间窗: Up to approximately 5 years
pCR rate after neoadjuvant therapy of perioperative population
时间窗: Up to approximately 5 years
次要结局
- Disease Control Rate (DCR) of the first-line population(Up to approximately 5 years)
- Duration of Response (DoR) of the first-line population(Up to approximately 5 years)
- Progression-free survival (PFS) of the first-line populations(Up to approximately 5 years)
- Major pathological response (MPR) rate of perioperative population(Up to approximately 5 years)
- R0 rate of perioperative population(Up to approximately 5 years)
- Event-free survival (EFS) of perioperative population(Up to approximately 5 years)
- Overall Survival (OS)(Up to approximately 5 years)
- Incidence and severity of AE(Up to approximately 5 years)
- Blood concentration of JSKN003(Up to approximately 2 years)
- Blood concentration of total antibodies for JSKN003(Up to approximately 2 years)
- Blood concentration of free toxins for JSKN003(Up to approximately 2 years)
- Serum concentration of KN026(Up to approximately 2 years)
- Serum concentration of Enlonstobart;(Up to approximately 2 years)
- Anti-drug antibodies (ADA) related to JSKN003(Up to approximately 2 years)
- Title: ADA related to KN026(Up to approximately 2 years)
- ADA related to Enlonstobart(Up to approximately 2 years)
研究者
相似试验
尚未招募
1 期
JSKN033 in Chinese Subjects with Advanced Malignant TumorsAdvanced Malignant TumorsNCT06770881Jiangsu Alphamab Biopharmaceuticals Co., Ltd430
撤回
2 期
Effect of Pembrolizumab and Cisplatin on Metastatic, Locally Recurrent or Inoperable Triple-Negative Breast CancerEstrogen Receptor NegativeHER2/Neu NegativeProgesterone Receptor NegativeRecurrent Breast CarcinomaTriple Negative Breast CancerMetastatic Breast CancerNCT03644589University of Washington
终止
1 期
A Study of IMGN901 for Patients With Advanced Solid Tumors and Extensive Stage Small Cell Lung CancerSmall Cell Lung CancerNCT01237678ImmunoGen, Inc.181
已完成
2 期
A Study of DKN-01 as a Monotherapy or in Combination With Paclitaxel in Patients With Recurrent Epithelial Endometrial or Epithelial Ovarian Cancer or CarcinosarcomaEndometrial CancerUterine CancerCarcinosarcomaOvarian CancerNCT03395080Leap Therapeutics, Inc.111
撤回
1 期
Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR CancersAdvanced Solid TumorMetastatic CancerHER2-positive Breast CancerHER2-positive Gastric CancerHER-2 Protein OverexpressionOvarian CancerEsophageal CancerEndometrium CancerNon Small Cell Lung CancerEGF-R Positive Non-Small Cell Lung CancerHead and Neck Squamous Cell CarcinomaTriple Negative Breast CancerColorectal CancerPancreatic CancerCervical CancerBladder CancerSarcomaNCT04464967NKGen Biotech, Inc.